Syntekabio has launched STB CLOUD worldwide. Running on SyntekabioÆs own supercomputing infrastructure, the new AI drug discovery cloud platform is driven by genomic big data and the latest AI technology. It can process small molecule drug discovery on any device, anytime and anywhere. STB CLOUD outperforms common Software as a Service (SaaS) options in the market. By integrating DeepMatcher, an AI-driven small molecule drug discovery platform, this new service has automated AI computing function within its own supercomputing hardware environment and
database into the cloud system. Improving standardization, simplification and automation of the existing computer-aided drug discovery (CADD) process optimizes the drug discovery and development process far better in terms of time, cost, accuracy and resources. It generates a comprehensive automatic report, including active substance candidates with usersÆ minimum input, for instance, only by inputting the name of the target protein related to a disease of interest. For the evaluation of automated drug discovery performance in STB CLOUD, DeepMatcher was used for 10 target proteins with a library of 120 million compounds available for quick purchase. The evaluation included compounds with known binding affinity as positive controls in the compound library and tracked the number of positive controls recovered during the DeepMatcher process, which is comprised of three steps: 3D screening, optimal pose and validation. After the first step, the average recovery rate was 31 percent among 1,000 top-ranked
candidates. At the completion of the final validation step (MD simulation), the recovery rate resulted in an average of 16% among 200 final-ranked candidates for 10 targets. These outstanding results prove not only the power of STB CLOUD but the potential of DeepMatcher itself in the overall drug discovery industry. Syntekabio is already working on further strengthening STB CLOUD, with a neoantigen prediction platform (NEO-ARS) and a multivariate biomarker prediction and discovery platform (PGM- ARSÖ), to be used for supporting clinical trials with a selection of patients in the near future. Additionally, the companyÆs new high-performance supercomputing center with 10,000 CPU/GPU computing servers is underway to be completed in the first half of 2023.